Co-Located with BIOTECHNICA 2009, Europe's No.1 Event in Biotechnology and Life Sciences
Day 1 | Day 2
WEDNESDAY, 7 OCTOBER
09:00-18:00 Exhibit Viewing
09:00-09:05 Chairperson’s Remarks
Gregory A. Weiss, Ph.D., Professor, Department of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
09:05-09:35 Engineering of Therapeutic Antibodies for Optimal Affinity and Biophysical Properties
Christilyn Graff, Ph.D., Senior Scientist, Protein Engineering, Biogen Idec
Selection of a therapeutic antibody hinges on both affinity for the target and appropriate biophysical properties, including propensity to aggregate, solubility, and stability. This presentation will cover the many approaches that one can take using phage display to improve antibodies with known good affinity for the target, but sub-optimum biophysical properties. Approaches presented include engineering the variable and constant domains of the antibody, as well as using families of antibodies to guide design of improved mutants. As different approaches can yield a range of results, it is advantageous to explore multiple routes to a solution.
09:35-10:05 Thermostability Engineering of a Soluble T-Cell Receptor Using Phage Display
Geir Åge Løset, Ph.D., Post-doctoral Fellow, Molecular Biosciences, University of Oslo
We have used phage display to engineer a soluble T-cell receptor to increased solubility and decreased susceptibility to aggregation. Random mutations were introduced in the V regions and mutants resistant to thermal denaturation were selected. Co-expression of the chaperone FkpA was critical for success – a finding of strong general interest for all combinatorial selection regimes. This is the first example to date of thermostability engineering of a soluble T-cell receptor by phage display.
10:05-10:20 Sponsored Presentation (Opportunity Available)
10:20-10:35 The Attana 200 System: Optimizing Expression, Selection and Molecular Characteristics
Alexander Kovacs, Ph.D., Global Product Manager, Attana AB
Attana AB is a world leading company in molecular interaction applications using the Quartz Crystal Microbalance technology. Our instruments are today employed by the Pharmaceutical and diagnostic industries as well as the academia, with customers in the US as well as through-out Europe. This presentation will discuss the solutions, applications and benefits of Attana's label-free and real-time technology in clone selection and molecular selection and characterisation. The presentation will also address how to obtain high quality data in pure and crude samples and applications such as off-rate screening, detailed kinetics, concentration determination and thermodynamic studies.
10:35-11:00 Coffee Break Sponsored by
11:00-11:30 Phage Display and Engineering of Membrane Proteins
Gregory A. Weiss, Ph.D., Professor, Department of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
Representing about a third of the human proteome, membrane proteins contribute key roles in molecular sensing, signaling, and transportation. Roughly half of all pharmaceuticals target membrane proteins. Despite their importance, membrane proteins have remained off-limits to phage display. Using a new type of helper phage, the Weiss Laboratory has reported display and engineering of membrane proteins.
11:30-12:00 Comprehensive Identification of Tumor-Associated Antigens via Isolation of Human Monoclonal Antibodies that May be Therapeutic
Yoshikazu Kurosawa, Ph.D., Director, Professor, Institute for Comprehensive Medical Science, Fujita Health University
We succeeded in identification of 28 tumor-associated antigens (TAAs) that were preferentially and abundantly expressed on the surface of malignant cells and in isolation of 435 human monoclonal antibodies (mAbs) that specifically bound to one of the 28 TAAs. I am going to present the strategy and the data showing how we can select proper targets for therapeutic Abs from among the TAAs and what characters are required for mAbs to be therapeutic reagents against solid cancers.
12:00-12:30 Apoptosis-Inducing ICAM-1 Antibody has Broad and Potent Anti-Myeloma Activity in Vivo
Björn Frendéus, Ph.D., BioInvent International AB
We previously developed combined target and drug discovery methodology enabling isolation of tumor cell apoptosis-inducing antibodies from the in vitro CDR shuffled human antibody library n-CoDeR®. Among several antibodies targeting different tumor cell associated receptors with documented apoptosis-inducing properties, antibodies specific for intercellular adhesion molecule-1 (ICAM-1) - a receptor not previously associated with tumor cell apoptosis – were obtained. We here characterize the ICAM-1 specific antibody BI-505 with respect to in vivo anti-tumor activity in different well-established myeloma disease models and explore mechanisms underlying its anti-tumor activity. Preliminary data indicate that the BI-505 epitope is frequently and highly expressed on plasma cells from multiple myeloma patients.
12:30-13:45 Lunch for Purchase in the Exhibit Hall and Exhibit Viewing
13:45 Close of Phage Display of Therapeutic Antibodies conference
For questions, please contact:
Christina Lingham
Executive Director, Conference
Cambridge Healthtech Institute
Phone: 781-972-5464
Fax: 781-972-5425
E-mail: clingham@healthtech.com
For exhibit and sponsorship information, please contact:
Carol Dinerstein
Cambridge Healthtech Institute
Phone: 781-972-5471
E-mail: dinerstein@healthtech.com